Oxcarbazepine in the prevention of epileptic syndromes in alcohol detoxification;Oxcarbacepina para la prevención de patología epiléptica en la desintoxicación alcohólica

Revista de Neurologia

Volumn 40, Issue 10, 2005, Pages 577-580

  Ponce Alfaro, Guillermo ^a   Rodriguez Jimenez R ^a   Ortiz, H ^a   Rubio, G ^b   Jimenez Arriero M A ^a   Palomo, T ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Servicio de Salud Mental Puente de Vallecas   (Spain)

Author keywords

Alcohol detoxification; Anticonvulsive drugs; Benzodiazepines; Convulsive seizures; Diazepam; Oxcarbazepine

Indexed keywords

DIAZEPAM; OXCARBAZEPINE; VITAMIN B GROUP; ANTICONVULSIVE AGENT; CARBAMAZEPINE; DRUG DERIVATIVE;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; ATAXIA; CONTROLLED STUDY; DETOXIFICATION; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; SEIZURE; SOMNOLENCE; ADULT; DELIRIUM TREMENS; EPILEPSY; MIDDLE AGED;

ADULT; ALCOHOL WITHDRAWAL DELIRIUM; ALCOHOLISM; ANTICONVULSANTS; CARBAMAZEPINE; EPILEPSY; HUMANS; MIDDLE AGED;

EID: 24644451286     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4010.2004592     Document Type: Article

References (37)

1. Kopelman MD. Alcohol brain damage. In Glass IB, ed. The international handbook of addictive behaviour. London: Routlege; 1991. p. 141-51.
2. Victor M. The effects of alcohol on the nervous system. In Mendelson JH, Mello NK, eds. Medical diagnosis and treatment of alcoholism. New York: McGraw-Hill; 1992. p. 2001-261.
3. Rubio-Valladolid G, Mata-Cala F, Santo-Domingo Carrasco J. Urgencias relacionadas con el consumo de alcohol. In Rubio-Valladolid G, Santo-Domingo Carrasco J, eds. Guía práctica de intervención en el alcoholismo. Madrid: Nilo; 2000. p. 175-91.
4. Samson HH. Neurobiology of alcohol abuse. TIPS 1992; 13: 206-11.
5. Williams D, McBride AJ. The drug treatment of alcohol withdrawal symptoms: a systematic review. Alcohol Alcohol 1998; 33: 103-15.
6. Lundqvist G. The clinical use of chlomethiazole. Acta Psychiatr Scand 1996; 42 (Suppl 92): 113-4.
7. Lejoyeux M, Solomon J, Adès J. Benzodiacepine treatment for alcohol-dependent patients. Alcohol Alcohol 1998; 33: 563-75.
8. Casariego CP. Utilidad de la carbamacepina en el tratamiento ambulatorio del síndrome de abstinencia alcohólico leve y moderado. Revista Española de Drogodependencias 1990; 15: 123-6.
9. Herranz JL, Argumosa A, Salas-Puig J, grupo español del estudio TRINOVA. Oxcarbacepina en monoterapia en 324 pacientes con crisis parciales (estudio TRINOVA). Rev Neurol 2004; 39: 601-6.
10. Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. A double blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989: 3: 70-6.
11. Reinikainen KJ, Keränen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double blind study. Epilepsy Res 1987: 1: 284-9.
12. Herranz JL, Argumosa A. Características e indicaciones de la oxcarbacepina. Rev Neurol 2002: 35 (Supl 1): S101-9.
13. Malcom R, Ballenger JC, Sturgis ET, Anton R. Double-blind controlled trial comparing carbamazepine to oxacepam treatment of alcohol withdrawal. Am J Psychiatry 1989; 146: 617-21.
14. Malcom R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002; 17: 1-7.
15. Stuppaeck CH, Pycha R, Whitworth AB, Oberbauer H, Fleischhacker WW. Carbamazepine versus oxacepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol 1992; 27: 153-8.
16. Gammer H. Carbamazepine (tegretol) in alcohol intoxications - a pilot study. Lakartidningen 1976; 73: 2818-20.
17. Poutamen P. Experience with carbamazepine in the treatment of withdrawal symptoms in alcohol abusers. Br J Addict 1979; 74: 201-4.
18. Bjorkvist SE, Isohanni M, Makela R, Malinen, L. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicenter double-blind comparison with placebo. Acta Psychiatr Scand 1976; 53: 333-42.
19. Soyka M, Morhart-Klute M, Horak M. A combination of carbamazepine and tiapride in outpatient alcohol detoxification. Eur Arch Psychiatry Clin Neurosci 2002; 252: 197-200.
20. Franz M, Dlabal H, Kunz S, Ulferts J, Gruppe H, Gallhofer B. Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole. A pilot study. Eur Arch Psychiatry Clin Neurosci 2001; 251: 185-92.
21. Hillbom ME. Alcohol withdrawal seizures: alternatives for treatment and prevention. Nord Psykiatr Tidsskr 1987; 41 (Suppl 17): 45-7.
22. Hillbom ME, Hjelm-Jäger M. Should alcohol withdrawals seizures be treated with anti-epileptic drugs? Acta Neurol Scand 1984; 69: 39-42.
23. Faigle JW, Menge GP. Pharmacokinetics and metabolic features of oxcarbazepine and their clinical significance; comparison with carbamazepine. Int Clin Psychopharmacol 1990; 5 (Suppl 1): S73-82.
24. McLean MJ, Schumutz M, Wamil AW, Olpe HR, Portet C. Oxcarbazepine: mechanism of action. Epilepsia 1994; 35 (Suppl 3): S5-9.
25. Wamil AW, Schmutz M, Portet C, Feldmann KF, McLean MJ. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol 1994; 271: 301-8.
26. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HF. Oxcarbazepine: preclinical anticonvulsants profile and putative mechanisms of action. Epilepsia 1993; 34 (Suppl 5): S47-50.
27. Tabakoff B, Hoffman PL. Neurobiology of alcohol. In Galanter M, Kleber HD, eds. Textbook of substance abuse treatment. 2 ed. Washington DC: American Psychiatric Press; 1999. p. 3-10.
28. Steinhoff BJ. Hyponatremic coma under oxcarbazepine therapy. Epilepsy Res 1992; 11: 67-70.
29. Schutz H, Feldmann KF, Faigle JW, Kriemler HP, Winkler T. The metabolism of 14C-oxcarbazepine in man. Xenobiotica 1986; 16: 769-78.
30. Degen PH, Flesh G, Cardot JM, Czendlik C, Dieterle W. Influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. Biopharmacol Drug Dispos 1994; 15: 510-26.
31. Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, et al. The effects of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994; 47: 161-7.
32. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-7.
33. Gaily E, Granström ML, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol 1997; 12: 496-8.
34. Gaily E, Granström ML, Liukkonen E. Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intel Disab Res 1998; 42 (Suppl 1): S41-5.
35. Glauser TA, Nigro M, Sachdeo R, Pasteris LA, Weinstein S, Abou-Khalil B, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000; 54: 2237-44.
36. Schachter SC, Vázquez B, Fisher RS, Laxer KD, Combs-Cantrell D, Faught E, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52: 732-7.
37. Peters H, Faulds D. Tiapride: a review of its pharmacology and therapeutical potential in the facilitation of alcohol withdrawal. Drugs 1994; 47: 1-24.